Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Achieves $20M Janssen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genmab Achieves $20M Janssen Milestone

The daratumumab collaboration progress is based on a study of the drug in a disease other than multiple myeloma

By: Betsy Louda

, Contract Pharma

Genmab’s DARZALEX (daratumumab) collaboration partner, Janssen Biotech, has triggered a $20 million milestone payment. The milestone relates to progress in the ongoing Phase III ANDROMEDA study of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in amyloidosis.
 

Daratumumab is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death.

 

“This milestone marks an important step in the development of daratumumab outside of multiple myeloma,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab. “There is currently no cure for amyloidosis and we look forward to seeing the results of daratumumab treatment in this indication.”   

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics